

Symbicort[®] (budesonide/formoterol) – First-time generic

- On July 31, 2023, <u>Viatris and Kindeva launched</u> an <u>AB-rated</u> generic version (<u>Breyna</u>[™]) of AstraZeneca's <u>Symbicort (budesonide/formoterol)</u> metered-dose inhaler.
 - Previously, <u>Prasco launched</u> an authorized brand alternative of Symbicort in January of 2020.
- Symbicort is approved for the treatment of asthma in patients 6 years of age and older, and for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD.
 - Symbicort 160/4.5 is the only strength indicated for the treatment of COPD.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.